|

225Ac-J591 Clinical Trials

2 actively recruiting trials across 2 locations

No change since July 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Weill Medical College of Cornell University2

Indications

Boston, Massachusetts1 trial

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1/2

Brooklyn, New York1 trial

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Brooklyn Methodist Hospital - New York Presbyterian

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.